Heghine Khachatryan: The Future of Anticoagulation Beyond DOACs
Heghine Khachatryan, Editor-in-Chief of Hemostasis Today, Head of Hemophilia and Thrombosis Center at Yeolyan Hematology and Oncology Center, reposted from JTH on LinkedIn, about a recent article by Holly Dobbing et al, adding:
”Beyond DOACs: The Future of Anticoagulation
The recently highlighted article in the Journal of Thrombosis and Haemostasis explores novel and experimental anticoagulant strategies beyond current DOACs — a rapidly evolving field with profound clinical implications.
While direct oral anticoagulants (DOACs) have transformed thrombosis management, significant unmet needs remain:
- Patients with high bleeding risk
- Mechanical heart valves
- Advanced renal impairment
- Antiphospholipid syndrome
- Recurrent thrombosis despite standard therapy
Emerging therapeutic targets such as Factor XI and XIa inhibitors, RNA-based approaches, and next-generation selective pathway modulation aim to provide:
- Effective thrombosis prevention
- Reduced bleeding liability
- More precise coagulation control
For clinicians working in thrombosis and hemostasis, this represents a paradigm shift — moving from broad anticoagulation toward mechanism-refined, safer antithrombotic strategies.
As we continue strengthening thrombosis care systems in Armenia and globally, staying aligned with these innovations is essential for advancing patient safety and equity in treatment access.
Highly recommended reading for hematologists, cardiologists, and clinical researchers.”
Quoting Journal of Thrombosis and Haemostasis (JTH)‘s post:
”Novel and Experimental Anticoagulant Strategies Beyond Current DOACs
Emerging anticoagulation strategies explore contact pathway inhibition, fibrin targeting, and natural anticoagulant pathway enhancement to address DOAC limitations, promising safer thrombosis treatment with reduced bleeding risks for cardiovascular disease management.”
Title: Novel and experimental anticoagulant strategies beyond current direct oral anticoagulants
Authors: Holly Dobbing, Katherine L. Webb, Robert Ariëns
Read the Full Article on JTH
Stay updated on all scientific advances with Hemostasis Today.
-
Jun 1, 2026, 15:24John Chuback: DVT Can Start With Symptoms Many People Brush Off
-
Jun 1, 2026, 15:20Venugopalan Unni: Guidelines for the Evaluation and Management of Acute Pulmonary Embolism in Adults
-
Jun 1, 2026, 15:10Smitirupa Mishra: Standardizing RBC Morphology Reporting – Why ICSH Guidelines Matter?
-
Jun 1, 2026, 14:54Davide Massimi: A Bloodless Approach to Third Space Endoscopy
-
Jun 1, 2026, 14:27Afshan Sumera: Plasma Proteomics Reveals Complement And Coagulation Disruption In Transfusion-Dependent Thalassemia
-
Jun 1, 2026, 13:44Milad Abdalla: Elevating Phlebotomy Standards – Why Order of Draw and Blood Cultures Matter
-
Jun 1, 2026, 13:39Abdul Mannan: The Moral Injury of Practising Haemato-Oncology in a Resource-Limited Setting
-
Jun 1, 2026, 13:34Filza Aslam: What Does a Patient Journey Partner Actually Do in Bleeding Disorders?
-
Jun 1, 2026, 13:33Darine Ghanem: Advancing Health Equity in Care at the LATAM Meeting